Last reviewed · How we verify
Chondrogen
Chondrogen is a Biologic drug developed by Meluha Life Sciences SDN BHD. It is currently in Phase 2 development. Also known as: Mesenchymal Stem Cell.
Chondrogen is a treatment that involves the delivery of adult human stem cells by intra-articular injection, specifically studied for recovery following partial medial meniscectomy and osteoarthritis of the knee. The mechanism of Chondrogen is classified as somatic cell supplemental therapy, according to ChEMBL.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Chondrogen |
|---|---|
| Also known as | Mesenchymal Stem Cell |
| Sponsor | Meluha Life Sciences SDN BHD |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy (PHASE1, PHASE2)
- A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy (PHASE1, PHASE2)
- Phase 2B Clinical Study of Chondrogen for Treatment of Knee Osteoarthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chondrogen CI brief — competitive landscape report
- Chondrogen updates RSS · CI watch RSS
- Meluha Life Sciences SDN BHD portfolio CI
Frequently asked questions about Chondrogen
What is Chondrogen?
Who makes Chondrogen?
Is Chondrogen also known as anything else?
What development phase is Chondrogen in?
Related
- Manufacturer: Meluha Life Sciences SDN BHD — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Mesenchymal Stem Cell
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing